Abilify (aripiprazole) is a prescription atypical antipsychotic that treats depression, schizophrenia, bipolar disorder, irritability related to autism, and specific Tourette's symptoms. While most ...

In addition to administration as a tablet, ABILIFY is available in a 1 mg/mL nonrefrigerated oral solution. The safety of doses of ABILIFY above 30 mg/day has not been evaluated in clinical trials.

It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, ...

PRINCETON, NJ and TOKYO, JAPAN, November 20, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...

The Food and Drug Administration announced its approval Monday for the first digital medicine—a melding of a long-standing drug for schizophrenia—Abilify (aripiprazole tablets)—with an edible sensor ...

The Food and Drug Administration (FDA) issued a first-of-its-kind approval on Monday, approving the first drug in the United States with a digital ingestion tracking system. The new pill, called ...

Otsuka has finally lost its battle with the FDA to prevent generics of its antipsychotic Abilify from hitting the market. A federal judge issued a final ruling against the Japanese drugmaker, a little ...

TOKYO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) ...

The FINANCIAL — Teva Pharmaceutical Industries Ltd., on April 28 announced the launch of the generic equivalent to Abilify (aripiprazole) Tablets, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, in the ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". TOKYO and REDWOOD CITY, Calif., Nov. 14, 2017 /PRNewswire/ -- Otsuka ...